A5010659953- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Bone and Joint Diseases
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Spine and Intervertebral Disc Pathology
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Ocular Diseases and Behçet’s Syndrome
- Macrophage Migration Inhibitory Factor
- Systemic Sclerosis and Related Diseases
- Osteomyelitis and Bone Disorders Research
- Musculoskeletal Disorders and Rehabilitation
- Inflammasome and immune disorders
- T-cell and B-cell Immunology
- Inflammatory mediators and NSAID effects
- Osteoarthritis Treatment and Mechanisms
- Musculoskeletal pain and rehabilitation
- Liver Diseases and Immunity
- Inflammatory Bowel Disease
- Sarcoidosis and Beryllium Toxicity Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Dermatology and Skin Diseases
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging and Analysis
Klinikum Bielefeld
2016-2025
Bielefeld University
2021-2025
Charité - Universitätsmedizin Berlin
2014-2024
Freie Universität Berlin
2000-2024
Humboldt-Universität zu Berlin
2008-2024
Sheba Medical Center
2024
Tel Aviv University
2024
University College London Hospitals NHS Foundation Trust
2024
National Institute for Health Research
2024
Ghent University
2016-2022
<h3>Objective:</h3> To validate and refine two sets of candidate criteria for the classification/diagnosis axial spondyloarthritis (SpA). <h3>Methods:</h3> All Assessment SpondyloArthritis international Society (ASAS) members were invited to include consecutively new patients with chronic (⩾3 months) back pain unknown origin that began before 45 years age. The first tested in entire cohort 649 from 25 centres, then refined a random selection 40% cases thereafter validated remaining 60%....
Distinguishing true cellulitis from its many imitators is challenging but critical if we are to avoid unnecessary use of antibiotics and delays in treatment. Common stasis dermatitis, lipodermatosclerosis, contact lymphedema, eosinophilic cellulitis, papular urticaria. Specific criteria do not exist for the diagnosis alert physician can find clues history physical examination that point toward cellulitis.
The field of spondyloarthritis (SpA) has experienced major progress in the last decade, especially with regard to new treatments, earlier diagnosis, imaging technology and a better definition outcome parameters for clinical trials. In present work, Assessment SpondyloArthritis international Society (ASAS) provides comprehensive handbook on most relevant aspects assessments spondyloarthritis, covering classification criteria, MRI <i>x</i> rays sacroiliac joints spine, complete set all...
Objective To determine the overall prevalence of spondylarthropathy (SpA) among whites. Methods screen for SpA symptoms, such as inflammatory back pain (IBP), joint swelling, psoriasis, and uveitis, or a specific family history, questionnaires were mailed to 348 blood donors (174 HLA-B27 positive 174 negative). From responding 273 persons (78%; 140 B27 positive, 133 negative), 126 selected further evaluation based on symptoms reported. Of this group, 90 agreed undergo physical examination...
<h3>Objective:</h3> Non-radiographic axial spondyloarthritis (SpA) is characterised by a lack of definitive radiographic sacroiliitis and considered an early stage ankylosing spondylitis. The objective this study was to develop candidate classification criteria for SpA that include patients with but also without sacroiliitis. <h3>Methods:</h3> Seventy-one possible SpA, most whom were lacking definite sacroiliitis, reviewed as "paper patients" 20 experts from the Assessment SpondyloArthritis...
<h3>Background:</h3> Magnetic resonance imaging (MRI) of sacroiliac joints has evolved as the most relevant modality for diagnosis and classification early axial spondyloarthritis (SpA) including ankylosing spondylitis. <h3>Objectives:</h3> To identify describe MRI findings in sacroiliitis to reach consensus on which are essential definition sacroiliitis. <h3>Methods:</h3> Ten doctors (two radiologists eight rheumatologists) from ASAS/OMERACT working group reviewed discussed three workshops...
Abstract Objective Ankylosing spondylitis (AS) is diagnosed late, because radiographs of the sacroiliac joints often do not show definite sacroiliitis at time disease onset. The aim this study was to investigate whether patients without radiographically defined sacroiliitis, referred as nonradiographic axial spondylarthritis (SpA), are different from with AS regard clinical manifestations and activity measures. Moreover, we sought identify determinants development radiographic sacroiliitis....
Chronic low back pain (LBP), the leading symptom of ankylosing spondylitis (AS) and undifferentiated axial spondyloarthritis (SpA), precedes development radiographic sacroiliitis, sometimes by many years.To assign disease probabilities to develop an algorithm help in early diagnosis SpA.Axial SpA comprises AS with predominant involvement. Clinical features include inflammatory (IBP), alternating buttock pain, enthesitis, arthritis, dactylitis, acute anterior uveitis, a positive family...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence these recommendations was only of indirect nature. These were re-evaluated light new insights. Based on results a systematic literature review expert opinion, task force rheumatologists, dermatologists, patients health professional developed an update 2012 recommendations. underwent intensive discussions, site voting subsequent anonymous electronic levels agreement with each item....
Inflammatory back pain (IBP) is an important clinical symptom in patients with axial spondyloarthritis (SpA), and relevant for classification diagnosis. In the present report, a new approach development of IBP criteria discussed.Rheumatologists (n = 13) who are experts SpA took part 2-day international workshop to investigate 20 possible SpA. Each expert documented presence/absence parameters typical IBP, judged whether was considered or absent based on received information. This judgement...
To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for management axial spondyloarthritis (axSpA).Following EULAR Standardised Operating Procedures, two systematic literature reviews were conducted on non-pharmacological and pharmacological treatment axSpA. In a task force meeting, evidence was presented, discussed, overarching principles updated, followed by voting.Five 15 with focus personalised medicine agreed: eight remained unchanged from...
Abstract Objective Back pain associated with ankylosing spondylitis (AS) is referred to as inflammatory back (IBP). The value of the clinical history in differentiating IBP from mechanical low (MLBP) has been investigated only a few studies. In this exploratory study, we sought evaluate individual features and compose compare various combinations for use classification diagnostic criteria. Methods We assessed 213 patients (101 AS 112 MLBP) younger than 50 years who had chronic pain. Single...
Abstract Objective There is increasing evidence that tumor necrosis factor α (TNFα) centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate efficacy anti‐TNFα therapy with etanercept, a 75‐kd receptor fusion protein, active AS. Methods multicenter trial had 2 phases: an initial placebo‐controlled period 6 weeks' duration observational phase lasting 24 weeks. Thirty patients AS were included. They randomized...
To assess prospectively the rates and to explore predictors of spinal radiographic progression over 2 years in a cohort patients with early axial spondylarthritis (SpA).Two hundred ten SpA from German Spondyloarthritis Inception Cohort were selected for this analysis based on availability radiographs at baseline after followup. Spinal scored by trained readers blinded, randomly order according modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). was defined as worsening mean mSASSS ≥2...
To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-axSpA (NCT01087762), an ongoing Phase 3 trial patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) non-radiographic axSpA (nr-axSpA).Patients active were randomised 1:1:1 to placebo, CZP 200 mg every 2 (Q2W) or 400 4 (Q4W). In total 325 randomised. Primary endpoint was ASAS20 (Assessment SpondyloArthritis international Society 20) response at week 12. Secondary outcomes...
<b>Background:</b> TNFα blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS). <b>Objective:</b> To identify parameters predicting the clinical response TNF AS. <b>Methods:</b> Patients AS participated two placebo controlled, randomised trials conducted Germany infliximab (n = 69) and etanercept 30), respectively. For inclusion either trial had high disease activity (BASDAI ⩾4) a spinal pain score (numerical rating scale 0–10) ⩾4 despite...
This paper presents the second update of Assessment in SpondyloArthritis international Society (ASAS) consensus statement on use anti-tumour necrosis factor (anti-TNF) agents patients with axial spondyloarthritis (SpA). A major change from previous recommendations is that fulfilling ASAS SpA criteria, which also include modified New York criteria for ankylosing spondylitis, can be treated anti-TNF agents. makes an earlier start disease process possible. mandatory pretreatment before started....
Abstract Objective To evaluate a magnetic resonance imaging (MRI) scoring system for the assessment of spinal inflammation in patients with ankylosing spondylitis (AS) who participated randomized, placebo‐controlled trial infliximab, and to examine whether infliximab is also effective reduction MRI‐proven inflammation. Methods Twenty AS (9 women 11 men, mean age 40.9 years) were examined at baseline after 3 months. Nine had received infusions (5 mg/kg body weight) weeks 0, 2, 6, placebo....
Melanoma treatment has been revolutionized over the past decade. Long-term results with immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a substantial number patients. These have prompted consideration how best to define long-term benefit cure. Now more than ever, oncologists should be aware outcomes demonstrated these newer their relevance decision-making. As first tumor type which I-O were approved, melanoma served as model other diseases....